Crisugabalin besilate capsules | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Haisco Pharmaceutical Group Co., Ltd.
- Medicine type
- Chemical medicine
- Therapeutic area
- Anesthesia & pain
- Indications recorded in the public source
- Treatment of diabetic peripheral neuropathic pain and postherpetic neuralgia in adults.
- Indication source and scope
- Source date(s): 2026-06, 2026-10-23. Manufacturer prescribing information for Mainland China. An approval or revision date is blank or a placeholder; the exact revision date is not confirmed. Evidence review: 23 October 2026.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Limited to: 1. Diabetic peripheral neuropathic pain in adults. 2. Postherpetic neuralgia.
- Insurance period
- 2025-01-01 to 2026-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.cnpharm.com/upload/resources/file/2025/03/18/170990.pdf
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.haisco.com/hsk/2026/06/26/fIfBddVkltWZx.pdf
Open the interactive record, public price references and discussions